The vanguard in cell and gene therapies for muscle disorders
MyoPax is developing a method for the isolation and cultivation of regenerative muscle stem cells.
This enables MyoPax to produce large high-purity populations of stem cells that they call PHSats: Primary Human Satellite cell derived muscle stem cells.
MyoPax is based in Berlin, Germany/Copenhagen, Denmark and is headed by the CEO and Co-founder Verena Schöwel-Wolf.
MyoPax joined NOME in 2022.